Brochure References · Mind Medicine Australia
Mind Medicine Australia logo Menu

Brochure References

[1] [2] [3] Australian Bureau of Statistics (2009), National Survey of Mental Health and Wellbeing: Summary of Results, 4326.0, 2007. ABS: Canberra.

[4] Productivity Commission (2019), Mental Health, Draft Report, Canberra

[5] De Maat, S., Dekker, J., Schoevers, R., & De Jonghe, F. (2006). Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Psychotherapy Research, 16(5), 566-578.

[6] Johnson, M et al. (2014). 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28-11:983-992

[6] Goldberg, S (2020). The experimental effects of psilocybin on symptoms of anxiety and depression. Psychiatry Research.
[7] Mithoefer, M.et al. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 1-11.

[8] Petri, G., et al(2014). Homological scaffolds of brain functional networks. Journal of The Royal Society Interface, 11(101), 20140873.
[9] Thomas, K., Malcolm, B., & Lastra, D. (2017). Psilocybin-assisted therapy: a review of a novel treatment for psychiatric disorders. Journal of psychoactive drugs, 49(5), 446-455.

[10] Schenberg, E. E. S. (2018). Psychedelic-assisted psychotherapy. Frontiers in pharmacology, 9, 733

[11] Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?. Progress in neuro-psychopharmacology and biological psychiatry, 84, 221-228.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×
It's time. Make your voice heard. Lodge a submission to the TGA supporting rescheduling of MDMA and Psilocybin. Closes May 27.